Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Copernicus Therapeutics
company
About
Copernicus Therapeutics, Inc. (CTI) is a clinical stage biopharmaceutical company
- 1 - 10
Details
- Last Funding Type
- Grant
- Industries
- Biotechnology
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Copernicus Therapeutics, Inc. (CTI) is a clinical stage biopharmaceutical company and a leader in the emerging field of precision medicine and gene therapy. Through their proprietary, non-viral, nucleic acid nanoparticle platform, they are able to achieve robust gene transfer in several tissues without the immune response and limited treatment window of AAV.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
$6.60M
Copernicus Therapeutics has raised a total of
$6.60M
in funding over 2 rounds. Their latest funding was raised on
Jun 30, 2008 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 30, 2008 | Grant | — | 1 |
|
— | Detail |
| Nov 20, 2002 | Series Unknown | $2M | 1 |
|
— | Detail |
| Jan 1, 1999 | Series Unknown | $4.60M | 1 |
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
3
3
Copernicus Therapeutics is funded by 3 investors.
Ohio Department of Development
and Veron International
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Grant |
|
|
Yes | Series Unknown |
|
|
Yes | Series Unknown |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
